Penpulimab
Penpulimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| penpulimab | Biologic Licensing Application | 2025-04-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
88 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 5 | 2 | 1 | 1 | 10 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | 1 | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 5 | 13 | 4 | — | 1 | 20 |
| Neoplasms | D009369 | — | C80 | 9 | 7 | 1 | — | — | 13 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 7 | 3 | — | 1 | 11 |
| Lymphoma | D008223 | — | C85.9 | 2 | 7 | 1 | — | 2 | 10 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | 6 | 1 | — | — | 8 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 2 | 3 | — | 2 | 8 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | 5 | 1 | — | — | 7 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 2 | 2 | — | 2 | 7 |
| Hodgkin disease | D006689 | — | C81 | 1 | 3 | 1 | — | — | 4 |
| Squamous cell neoplasms | D018307 | — | — | 1 | 1 | 1 | — | 1 | 3 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | D002294 | — | — | 2 | 6 | — | — | 1 | 7 |
| Colorectal neoplasms | D015179 | — | — | 3 | 4 | — | — | — | 6 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 3 | — | — | 2 | 5 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 4 | — | — | — | 4 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | 3 | — | — | 1 | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 4 | — | — | — | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 2 | — | — | 1 | 3 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 2 | — | — | — | 2 |
| Digestive system neoplasms | D004067 | — | — | — | 2 | — | — | — | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | 1 | 2 |
Show 25 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell carcinoma | D018288 | — | — | — | — | — | — | 1 | 1 |
| Thyroid diseases | D013959 | — | E00-E07 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Penpulimab |
| INN | penpulimab |
| Description | Penpulimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297571 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | IBS1BZ4E4I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 408 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use